For continuation versus noncontinuation, the weighted prevalence ratios were 1.29 (95 percent confidence interval, 0.82 to 2.06), 1.08 (95 percent confidence interval, 0.84 to 1.40), and 1.21 (95 percent confidence interval, 0.83 to 1.82) for small for gestational age, large for gestational age, and MCM, respectively."Accumulated evidence provides some reassurance about risk for malformations after inadvertent exposure in women who become pregnant while using GLP-1 RAs," the authors write.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter
Yes, Wegovy is approved by the FDA to reduce cardiovascular risk in adults with established heart disease who are also obese or overweight
This proportional muscle loss is consistent with weight loss from any cause, including dietary restriction or bariatric surgery, but the rapidity of weight loss with these medications may make this effect more clinically apparent
Researchers can locate primary literature via PubMed using the CAS number listed below
It is vital to maintain high water intake while on this medication